AMENDMENTS TO THE CLAIMS

The following Listing of the Claims replaces all prior claims in the application.

1. (Original): β-carboline derived guanidine alkaloid, tiruchenduramine of the Formula 1



1

isolated from an ascidian *Synoicum macroglossum* and its derivatives thereof.

2. (Original): A compound as claimed in claim 1 selected from the following:



1. $R_1=R_2=R_3=H$, n=2
2. $R_1=R_2=R_3=H$, n=3
3. $R_1=R_2=R_3=H$, n=4
4. $R_1=R_2=R_3=H$, n=5
5. $R_1=R_2=R_3=H$, n=6



6. $R_1=R_2=R_3=H$, n=2
7. $R_1=R_2=R_3=H$, n=3
8. $R_1=R_2=R_3=H$, n=4
9. $R_1=R_2=R_3=H$, n=5
10. $R_1=R_2=R_3=H$, n=6



11. R_1= Piperzine, $R_2=R_3=H$, n=2
12. R_1= Piperzine, $R_2=R_3=H$, n=3
13. R_1= Piperzine, $R_2=R_3=H$, n=4
14. R_1= Piperzine, $R_2=R_3=H$, n=5
15. R_1= Piperzine, $R_2=R_3=H$, n=6



16. R_1= Piperzine, $R_2=R_3=H$, n=2
17. R_1= Piperzine, $R_2=R_3=H$, n=3
18. R_1= Piperzine, $R_2=R_3=H$, n=4
19. R_1= Piperzine, $R_2=R_3=H$, n=5
20. R_1= Piperzine, $R_2=R_3=H$, n=6

3. (Original): A process for the preparation of β-carboline derived guanidine alkaloid tiruchenduramine of Formula 1



1

which comprises subjecting an ascidian to solvent extraction.

4. (Original): A process as in claim 3 wherein said ascidian is *Synoicum macroglossum*.

5. (Previously Presented): A process as claimed in claim 3 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

6. (Currently Amended): A process as claimed in claim ~~4~~ 5 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

7. (Currently Amended): A process as claimed in claim ~~5~~ 6 wherein said dichloromethane and methanol are used in a ratio of 1:1.

8. (Currently Amended): A process as claimed in claim ~~5~~ 7 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

9. (Previously Presented): A process as claimed in claim 8 wherein said water extract is lyophilized and the residue is triturated with methanol.

10. (Currently amended): A process as claimed in claim 5 wherein ~~siad~~ said purification comprises a Sephadex LH-20 column chromatography.

11. (Previously Presented): A pharmaceutical composition comprising as an active ingredient a compound of Formula 1, and



1

a pharmaceutically acceptable carrier, vehicle or excipient.

12. (Previously Presented): A pharmaceutical composition comprising as an active ingredient a compound as claimed in claim 2 and a pharmaceutically acceptable carrier, vehicle or excipient.

13 (Previously Presented): A composition claimed in claim 11 wherein said composition is used for the treatment of diabetic disorders and wherein said active ingredient is present in an amount of about 78.8 μg.

14. (Previously Presented): A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

15 (Previously Presented): A pharmaceutical composition comprising a first therapeutic agent consisting of a β-carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20 and a second therapeutic agent different from said first therapeutic agent.

16. (Previously Presented): A composition as claimed in claim 15 wherein said second therapeutic agent is selected from alkylating agents, antimetabolites, vinca alkaloids, antibiotics, cytokines, growth factors and non-steroidal anti-inflammatory drugs.

17. (Currently Amended): A method of treating diabetic disorders in a mammal in need thereof wherein the method comprises administration of a β-carboline derivative guanidine

alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20 ~~in the treatment of diabetic disorders~~.

18. (Previously Presented): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a β-carboline derivative guanidine alkaloid, tiruchenduramine selected from the group consisting of compounds 1 through 20.

19. (Previously Presented): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 11.

20. (Previously Presented): A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

21. (Previously Presented): A composition claimed in claim 12 wherein said composition is used for the treatment of diabetic disorders and wherein said active ingredient is present in an amount of about 78.8 μg.

22. (New): A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

23. (New): A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

24. (New): A process as claimed in claim 4 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

25. (New): A process as claimed in claim 24 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

26. (New): A process as claimed in claim 25 wherein said dichloromethane and methanol are used in a ratio of 1:1.

27. (New): A process as claimed in claim 26 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

28. (New): A process as claimed in claim 27 wherein said water extract is lyophilized and the residue is triturated with methanol.

29. (New): A process as claimed in claim 6 wherein said purification comprises a Sephadex LH-20 column chromatography.

30. (New): A process as claimed in claim 7 wherein said purification comprises a Sephadex LH-20 column chromatography.

31. (New): A process as claimed in claim 8 wherein said purification comprises a Sephadex LH-20 column chromatography.

32. (New): A process as claimed in claim 9 wherein said purification comprises a Sephadex LH-20 column chromatography.

33. (New): A process as claimed in claim 24 wherein said purification comprises a Sephadex LH-20 column chromatography.

34. (New): A process as claimed in claim 25 wherein said purification comprises a Sephadex LH-20 column chromatography.

35. (New): A process as claimed in claim 26 wherein said purification comprises a Sephadex LH-20 column chromatography.

36. (New): A process as claimed in claim 27 wherein said purification comprises a Sephadex LH-20 column chromatography.

37. (New): A process as claimed in claim 28 wherein said purification comprises a Sephadex LH-20 column chromatography.

38. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 12.

39. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 13.

40. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 14.

41. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 15.

42. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 16.

43. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 20.

44. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 21.

45. (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 22.

46: (New): A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 23.

47. (New): A composition of claim 16, wherein the non-steroidal anti-inflammatory is aspirin.